| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/14622416.7.6.889 |
| P698 | PubMed publication ID | 16981848 |
| P2093 | author name string | Rashmi R Shah | |
| P2860 | cites work | Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias | Q24311437 |
| Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy | Q24676890 | ||
| Herb-drug interactions: a literature review | Q28176037 | ||
| Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity | Q44772641 | ||
| Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations | Q44796890 | ||
| Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy | Q44990224 | ||
| A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin | Q45057856 | ||
| Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? | Q46466455 | ||
| Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions | Q46813333 | ||
| Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. | Q47618340 | ||
| Genetical and geographic studies on isoniazid inactivation | Q47810911 | ||
| Concomitant use of antipsychotics and drugs that may prolong the QT interval | Q48031488 | ||
| Studies on the metabolism of perhexiline in man. | Q50177316 | ||
| Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. | Q50195151 | ||
| Genetic polymorphisms of CYP2C8 in Japanese population. | Q54772646 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics | Q28244427 | ||
| Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response | Q28252209 | ||
| Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy | Q28328162 | ||
| Impaired oxidation of debrisoquine in patients with perhexiline neuropathy | Q28366143 | ||
| Pharmacogenetics of antihypertensive drug responses | Q28645953 | ||
| Risk stratification in the long-QT syndrome. | Q33148941 | ||
| The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome | Q33151279 | ||
| Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy | Q33332618 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events | Q34214671 | ||
| Pharmacogenetics of antidepressant medication intolerance | Q34265653 | ||
| Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity | Q34332730 | ||
| The role of metabolic activation in drug-induced hepatotoxicity | Q34410432 | ||
| Pharmacogenomics: the inherited basis for interindividual differences in drug response | Q34433440 | ||
| Pharmacogenetics in clinical practice: considerations for testing | Q34499056 | ||
| Pharmaco-metabonomic phenotyping and personalized drug treatment | Q34515169 | ||
| Impaired oxidation of debrisoquine in patients with perhexiline liver injury | Q34526158 | ||
| Gemfibrozil greatly increases plasma concentrations of cerivastatin | Q34530003 | ||
| Clinical pharmacokinetics of atomoxetine | Q34557871 | ||
| CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis | Q34568319 | ||
| Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter | Q34649624 | ||
| Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? | Q34706835 | ||
| Food-drug interactions | Q34716965 | ||
| The significance of QT interval in drug development | Q34808276 | ||
| A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. | Q34979818 | ||
| Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. | Q34994253 | ||
| Changes in prescribed drug doses after market introduction | Q34994259 | ||
| Pharmacogenetics in drug regulation: promise, potential and pitfalls | Q35038052 | ||
| Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience | Q35157450 | ||
| Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges | Q35218382 | ||
| Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease | Q35631353 | ||
| Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing | Q35645901 | ||
| Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. | Q35705858 | ||
| Moving towards individualized medicine with pharmacogenomics | Q35784527 | ||
| Polymorphic hydroxylation of perhexiline in vitro | Q35825349 | ||
| Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead | Q35908561 | ||
| Pharmacogenetics-based new therapeutic concepts | Q35956177 | ||
| Clinical consequences of cytochrome P450 2C9 polymorphisms | Q36002222 | ||
| Food-drug interactions via human cytochrome P450 3A (CYP3A). | Q36016526 | ||
| Interactions between herbal and conventional medicines | Q36082038 | ||
| Do preclinical testing strategies help predict human hepatotoxic potentials? | Q36086429 | ||
| Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance | Q36131028 | ||
| Measuring the value of pharmacogenomics | Q36138347 | ||
| Pharmacogenomics and acquired long QT syndrome | Q36192679 | ||
| Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease | Q36209752 | ||
| Drug-induced torsades de pointes: the evolving role of pharmacogenetics | Q36299203 | ||
| Clinical pharmacogenetics of irinotecan (CPT-11). | Q36300812 | ||
| Applications of AmpliChip CYP450. | Q36306661 | ||
| Pharmacogenetics of irinotecan metabolism and transport: an update | Q36306816 | ||
| Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance | Q36350528 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Metabolic therapeutics in angina pectoris: history revisited with perhexiline | Q36392401 | ||
| Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer | Q36410400 | ||
| Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant | Q37356747 | ||
| Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia | Q39437206 | ||
| Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity | Q40379756 | ||
| Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. | Q40442584 | ||
| Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes | Q40496732 | ||
| Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients | Q40518383 | ||
| Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. | Q40773486 | ||
| Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose | Q42125291 | ||
| Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. | Q42245956 | ||
| Perhexiline maleate-associated hepatic injury prevalence and characteristics | Q42272282 | ||
| Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions | Q43648681 | ||
| Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism | Q44097585 | ||
| Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. | Q44243126 | ||
| QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients | Q44263549 | ||
| Why aren't lower, effective, OTC doses available earlier by prescription? | Q44263690 | ||
| Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients | Q44314823 | ||
| Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis | Q44385947 | ||
| A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus | Q44431079 | ||
| Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers | Q44532794 | ||
| Gemfibrozil considerably increases the plasma concentrations of rosiglitazone | Q44536345 | ||
| Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status | Q44600111 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 889-908 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Can pharmacogenetics help rescue drugs withdrawn from the market? | |
| P478 | volume | 7 |
| Q53168186 | 'Drug reactions, enzymes, and biochemical genetics': 50 years later. |
| Q30538150 | A cell-based biosensor for real-time detection of cardiotoxicity using lensfree imaging |
| Q37424977 | A combined-cross analysis reveals genes with drug-specific and background-dependent effects on drug sensitivity in Saccharomyces cerevisiae |
| Q36146270 | A comparative analysis of protein targets of withdrawn cardiovascular drugs in human and mouse |
| Q33479407 | A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel |
| Q30585177 | A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data |
| Q42194344 | A simple approach discriminating cardio-safe drugs from toxic ones |
| Q34165511 | Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. |
| Q46307567 | An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data |
| Q89484527 | An Introduction to Computational Modeling of Cardiac Electrophysiology and Arrhythmogenicity |
| Q46145054 | An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility |
| Q37689202 | An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk |
| Q35101016 | An optical multi-sensing system for detection of cardiovascular toxicity. |
| Q33894413 | Asparagine synthetase: a new potential biomarker in ovarian cancer |
| Q30852962 | Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database |
| Q30833397 | Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip |
| Q38454536 | Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies |
| Q41783099 | Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development |
| Q57818505 | Cardiovascular disease models: A game changing paradigm in drug discovery and screening |
| Q46558929 | Cellular imaging predictions of clinical drug-induced liver injury |
| Q36745692 | Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System |
| Q38074715 | Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels |
| Q38082420 | Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? |
| Q35819331 | Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk |
| Q27006580 | Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? |
| Q46455559 | Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany |
| Q37649640 | Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations |
| Q37156289 | Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period |
| Q51254669 | GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. |
| Q36288606 | Genetic variation in the cysteine biosynthesis pathway causes sensitivity to pharmacological compounds |
| Q28554426 | Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market |
| Q38101884 | Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives |
| Q35036150 | How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? |
| Q38240972 | Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line. |
| Q34407398 | Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. |
| Q33833264 | Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels |
| Q42361532 | Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics |
| Q38447279 | In silico prediction of hERG inhibition |
| Q89278554 | Intact Cell Lipidomics Reveal Changes to the Ratio of Cardiolipins to Phosphatidylinositols in Response to Kanamycin in HeLa and Primary Cells |
| Q37735092 | Interactions between herbal remedies and medicinal drugs--considerations about Cuba |
| Q30656460 | Machine learning plus optical flow: a simple and sensitive method to detect cardioactive drugs |
| Q34953730 | Model-based evaluation of drug-induced QTc prolongation for compounds in early development |
| Q37068868 | Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations |
| Q33535332 | Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method |
| Q46686425 | Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities |
| Q37593391 | Modification of distinct ion channels differentially modulates Ca2+ dynamics in primary cultured rat ventricular cardiomyocytes |
| Q39300182 | Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q38909233 | Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel |
| Q38907804 | Pleiotropic mechanisms of action of perhexiline in heart failure |
| Q47566249 | Precision medicine: does ethnicity information complement genotype-based prescribing decisions? |
| Q45944023 | Predicting drug safety and communicating risk: benefits of a Bayesian approach. |
| Q38223668 | QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. |
| Q36989859 | Routine pharmacogenetic testing in clinical practice: dream or reality? |
| Q48309631 | Safety Pharmacology Society: 9th Annual Meeting |
| Q37892114 | Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society |
| Q38464750 | The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation |
| Q46869983 | The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality? |
| Q37838120 | The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example |
| Q45948688 | The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. |
| Q42707969 | The effect on rat embryonic heart rate of Na+, K+, and Ca2+ channel blockers, and the human teratogen phenytoin, changes with gestational age. |
| Q39749838 | The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling |
| Q53811688 | The validation of an LC-MS/MS assay for perhexiline and major hydroxy metabolites, and its application to therapeutic monitoring in patient plasma. |
| Q26799470 | Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening |
| Q28068710 | Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? |
| Q39183378 | What can nanosafety learn from drug development? The feasibility of "safety by design". |
| Q56018113 | Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine |
| Q58572183 | Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty |
| Q46876867 | miR-208a as a biomarker of isoproterenol-induced cardiac injury in Sod2+/- and C57BL/6J wild-type mice |
| Q26778918 | microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment |
Search more.